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ABSTRACT 
 
Background: Prognostic models for children starting antiretroviral therapy (ART) in Africa are 
lacking. We developed models to estimate the probability of death during the first year receiving 
ART in Southern Africa. 
Methods: We analyzed data from children ≤10 years old who started ART in Malawi, South 
Africa, Zambia or Zimbabwe from 2004-2010. Children lost to follow-up or transferred were 
excluded. The primary outcome was all-cause mortality in the first year of ART. We used 
Weibull survival models to construct two prognostic models: one with CD4%, age, WHO 
clinical stage, weight-for-age z-score (WAZ) and anemia and one without CD4%, because it is 
not routinely measured in many programs. We used multiple imputation to account for missing 
data.  
Results: Among 12655 children, 877 (6.9%) died in the first year of ART. 1780 children were 
lost to follow-up/transferred and excluded from main analyses; 10875 children were included.  
With the CD4% model probability of death at 1 year ranged from 1.8% (95% CI: 1.5–2.3) in 
children 5-10 years with CD4% ≥10%, WHO stage I/II, WAZ ≥-2 and without severe anemia to 
46.3% (95% CI: 38.2–55.2) in children <1 year with CD4% <5%, stage III/IV, WAZ< -3 and 
severe anemia. The corresponding range for the model without CD4% was 2.2% (95% CI: 1.8–
2.7) to 33.4% (95% CI: 28.2-39.3).  Agreement between predicted and observed mortality was 
good (C-statistics=0.753 and 0.745 for models with and without CD4% respectively).  
Conclusion: These models may be useful to counsel children/caregivers, for program planning 
and to assess program outcomes after allowing for differences in patient disease severity 
characteristics. 
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Despite increased access to antiretroviral therapy (ART) for HIV-infected children in low-
income settings, mortality remains high. In 2010, an estimated 230000 children died of AIDS in 
sub-Saharan Africa.1 While many deaths occur in untreated patients,2 mortality remains high 
during the first year of ART, especially for children starting therapy with advanced disease.3-5 
Knowing the short term prognosis associated with particular disease severity characteristics is 
important for individual children initiating ART and their caregivers, as well as for clinicians and 
for program planning. Further, comparison of actual mortality outcomes with predictions from a 
prognostic model that is generalizable across settings may be useful for benchmarking the 
quality of health care provision. While models of pediatric pre-ART mortality have been 
developed for high and low-income settings and used to inform decisions regarding treatment 
initiation,6-9 prognostic models of mortality on ART have to date only been developed for 
adults.10-12  
The characteristics associated with mortality in children starting ART have been well 
described.3-5,13-20 However, the combined power of different disease severity markers to predict 
mortality and the absolute mortality risk associated with these markers remains unknown. Young 
children and those with low CD4% or advanced clinical disease are at high risk of morbidity and 
mortality.3,4,13,18,20 HIV-1 RNA level and anemia are also independent mortality risk factors, 
although HIV-RNA is less predictive than CD4.13,15,21 However, in low income settings, 
measurement of many of these prognostic factors, including CD4, is often unavailable.22 
The International epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) 
Collaboration includes data from children starting ART at 11 treatment programs in a range of 
settings in four countries.3,20 We aimed to use these data to develop a prognostic model that 
estimates the cumulative probability of death at 3, 6 and 12 months after starting ART according 
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to age, and prognostic factors commonly measured in resource-limited settings. Separate models 
were developed for settings with and without access to CD4% at ART initiation. 
 
METHODS 
Treatment programs  
IeDEA-SA is a regional collaboration of ART programs, which is part of a larger international 
network.23 Data are collected at ART initiation and follow-up visits and regularly transferred to 
data centers at the Universities of Cape Town, South Africa, and Bern, Switzerland. All sites 
have ethical approval to collect data and participate in IeDEA-SA. This analysis was based on 
data from 11 programs in four countries, including eight clinics in three provinces in South 
Africa (Red Cross Children’s Hospital, Khayelitsha and Gugulethu ART Programs and 
Tygerberg Academic Hospital, Western Cape; McCord Hospital and Hlabisa HIV Treatment and 
Care Program, Kwazulu-Natal; Harriet Shezi Children’s Clinic and Rahima Moosa Mother and 
Child Hospital, Gauteng) and one program each in Zambia (Ministry of Health and Centre for 
Infectious Disease Research in Zambia program [MoH-CIDRZ]; Lusaka), Malawi (Lighthouse 
Trust Clinic at Kamuzu Central Hospital; Lilongwe) and Zimbabwe (Newlands Clinic; Harare). 
Inclusion criteria 
All HIV-infected, ART-naïve (except for antiretrovirals to prevent vertical transmission) 
children who initiated treatment with ≥3 antiretrovirals at age ≤10 years between 1 January 2004 
and 31 January 2010 were eligible. Children with <1 year of potential follow-up (ART initiation 
<1 year prior to site database closure) were excluded. Children were excluded from the main 
analysis if, within 6 months of starting ART, they were lost to follow-up (LTFU) or transferred 
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out (TFO) to a different treatment site. As clinic visits may be up to 6 months apart, LTFU was 
defined as the last visit being ≥270 days before database closure.  
Outcomes and prognostic models 
We used an intention-to-continue-treatment analysis, ignoring treatment changes and 
interruptions. The outcome was all-cause mortality during the first year on ART. Follow-up was 
censored on the earliest of: date of death, last visit date +90 days in children LTFU/TFO, or 1 
year after ART initiation (Supplementary Figure S1). The 11 cohorts were grouped into five 
geographic regions as some cohorts had small patient numbers. Three regions were provinces 
within South Africa where ART programs at different sites are coordinated by provincial 
Departments of Health (Western Cape, Kwazulu-Natal and Gauteng). The fourth region 
comprised two cohorts with similar patient characteristics in Malawi and Zimbabwe, while the 
MoH-CIDRZ cohort (Zambia) comprised the fifth region. Treatment initiation criteria at these 
sites were based on WHO and national guidelines at the time. In South Africa, the recommended 
first-line regimen was 2 nucleoside reverse transcriptase inhibitors (NRTI) plus either 
lopinavir/ritonavir (children <3 years or <10kg) or efavirenz (children > 3 years and >10kg). In 
Malawi, Zimbabwe and Zambia 2 NRTIs plus nevirapine was the recommended first-line for all 
children. 
The following prognostic variables measured at ART initiation were considered for inclusion in 
a prognostic model and associations with mortality were explored using Kaplan-Meier survival 
curves in the pre-specified categories of age (<1 year, 1 year, 2-4 years, 5-10 years); WHO 
Clinical Stage (I/II compared to III/IV); CD4% (<5, 5-9.9, 10-14.9; ≥15); weight-for-age z-score 
(WAZ) calculated using WHO 2006 standards (<-3.00; -3.00 to -2.01, -2.00 to -1.01 and ≥-1.00 
standard deviations below mean)24 and anemia defined using CDC classification that 
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incorporates both hemoglobin and age.25 Apart from age and gender, data on prognostic 
variables were not recorded for all patients. Missing data were modeled using multiple 
imputation by chained equations, with 25 imputed datasets.26-29 The following variables were 
used in imputation equations: cohort, sex, age, WHO Stage, CD4%, WAZ, hemoglobin, 
interactions between age, CD4% and WAZ, survival time and mortality indicator. Log or square 
root transformations were used for non-normally distributed variables. Weibull proportional 
hazards models were used to explore crude and adjusted associations between prognostic 
variables and mortality. 
A set of candidate models (with and without CD4%) were selected using the Akaike Information 
Criterion (AIC). These were flexible parametric survival models30 with spline smoothing of the 
baseline hazard to model the steep mortality during the first 3 months of treatment. We used a 
system of leave-one-out cross-validation to select the most generalizable models with and 
without CD4%.31,32 This method fits the model using data from four regions and tests 
discrimination of predictions of the model when applied to the omitted fifth region. This was 
repeated sequentially rotating the omitted region. Discrimination was assessed using the D-
statistic (averaged across the imputed datasets) which measures the prognostic separation 
between the survival distributions for two independent prognostic groups.32 We calculated the D-
statistic for the model fitted on the four regions and applied to the omitted region (Dtest) and 
compared this to the D-statistic for the model when coefficients were re-estimated using data 
only from the omitted region (Dr). The difference (Dr-Dtest) is a measure of the degradation in 
model fit and discrimination when applied to independent data compared with when applied to 
the data used to estimate the model coefficients. Models with a low AIC score, high Dtest and low 
Dr-Dtest were favored. 
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Concordance between predicted mortality and observed mortality for the final selected models 
was assessed using Harrell’s C-statistic (0.5 = agreement expected by chance; 1 = perfect 
agreement). The explained variation (R2) of the final selected models was calculated.33,34 Model 
calibration was assessed by comparing Kaplan-Meier curves of observed mortality with curves 
predicted from the model for groups with poor to good prognosis, and for each region. All 
analyses were conducted in STATA version 12.0 (STATA Corporation, College Station, Texas).  
Sensitivity analyses 
In sensitivity analyses we included children LTFU/TFO within six months of starting treatment. 
We examined Kaplan-Meier estimates of one-year mortality first censoring their follow-up at the 
last visit date +90 days, and then assuming 30% and 50% mortality in those LTFU/TFO with 
time to death randomly assigned based on the distribution in those not LTFU/TFO. Finally, we 
developed models including children LTFU/TFO, censoring follow-up time at the last visit date 
+90 days.  
 
RESULTS 
In the 11 treatment programs, 12655 children started ART. 1780 children (14%) were LTFU or 
TFO within 6 months of ART start and excluded from the main analyses. The main analysis 
included 10875 children (70% ≥2 years old) with 10204 child-years of follow-up (Table 1). Most 
children had advanced disease at ART initiation (72% WHO Clinical Stage III/IV; median [IQR] 
CD4%: 13% [8-19]). There was considerable between-region heterogeneity in age and disease 
severity; the percentage of children <1 year ranged from 3% to nearly 30%; the percentage with 
WHO Stage III/IV disease ranged from approximately 60% to >90%. There was substantial 
missing data on many covariates; anemia and CD4% were not reported for 37% (range across 
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regions: 18-88%) and 32% (16-56%) of children respectively. The estimated cumulative 
mortality by 1 year after ART start was 8.6% (95% CI: 8.0-9.2) (range across regions: 5.8%-
10.5%). 
The crude and adjusted associations between prognostic variables and mortality are shown in 
Table 2 (a). In adjusted analyses there was a significant interaction between age and both CD4% 
(p=0.028) and WAZ (p=0.002). The effect of an increase in either of these variables had a 
greater impact on reducing mortality risk in older children compared to younger children (Table 
2 [b]), although mortality overall was lower for older children.  
The two final models selected by internal-external cross-validation included age (in four 
categories), clinical stage (two), WAZ (three) and anemia (two), with one model additionally 
including CD4% (in three categories, Table 3). There were thus 144 risk groups (model with 
CD4%) or 48 risk groups (model without CD4%). The C-statistics over the entire first year on 
ART were 0.753 and 0.745 for the models with and without CD4% respectively. Concordance 
was lower when restricting to the second six months on ART (C-statistics of 0.708 and 0.705 for 
models with and without CD4% respectively). The R2 values were 32.1% and 31.1% for the 
whole first year and 23.6% and 23.9% for the second six months for the models with and without 
CD4% respectively. As hemoglobin was imputed for a large proportion of children, model 
diagnostics were recalculated restricted to children in whom hemoglobin was recorded. This 
resulted in slightly higher C-statistics (0.762 [with CD4%] and 0.754 [no CD4%]) and R2 (33.8% 
[with CD4%] and 32.9% [no CD4%]) for both models with very little difference between the two 
models. 
For both models, predicted mortality closely followed observed mortality for five prognostic 
groups of children with approximately 20% of deaths in each group (Figure 1[a]). Within each 
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region predicted and observed mortality for groups of children with different prognosis were also 
similar (Figure 1[b]), indicating generalizability of the models. The majority of children (57% 
[model with CD4%] and 58% [model without CD4%] were in the group with a good prognosis 
and one-year mortality <5%. Predicted mortality from the model with CD4% closely 
approximated observed mortality for all regions except Kwazulu-Natal (observed>predicted) and 
Malawi & Zimbabwe (observed<predicted) (Figure 1[c]). Predicted mortality from the model 
without CD4% only approximated observed mortality closely for CIDRZ (figure 1[b]). This was 
the only region where <20% of hemoglobin values were missing. In other regions, hemoglobin 
may not have been well imputed, particularly in Gauteng and Malawi & Zimbabwe where >60% 
of values were missing.  
Children age <1 year in clinical stage III/IV with WAZ <-3, severe anemia and CD4% <5 had 
the highest predicted cumulative mortality at one year (46.3%) and children age 5-10 years in 
stage I/II with WAZ ≥-2, no severe anemia and CD4% >10 the lowest mortality (1.8%). 
Predictions for all combinations of prognostic variables are shown in appendix Table S1. 
The 1780 children LTFU/TFO within the first six months of treatment were younger and had 
more advanced disease compared to those included (appendix Table S2). In sensitivity analyses 
that included these children, Kaplan-Meier one-year mortality estimates ranged from 7.2% 
(censoring children LTFU/TFO at last visit date +90 days) to 11.6% and 14.4% (assuming 30% 
and 50% mortality in those LTFU/TFO respectively). When developing the prognostic models 
including all children (censoring children LTFU/TFO at last visit date +90 days ) the predicted 
cumulative one-year mortality for the best and worst prognostic groups ranged from 1.72% to 
39.0% (CD4% model) and from 2.1% to 27.7% (model without CD4%). The corresponding C-
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statistics were 0.741 and 0.733 and R2 values were 29.5% and 28.3% respectively, which were 
very similar to the main analysis.  
 
DISCUSSION 
Main findings 
These prognostic models for one year mortality in children commencing ART are generalizable 
with good discrimination and prognostic separation. The majority of children (>55%) starting 
ART and remaining in care have a one year mortality risk of ≤5%, with 6% of children having 
>20% predicted risk of dying. For predicting mortality on ART, low cost prognostic markers 
such as WAZ and anemia may be almost as good as CD4%.  
Overall mortality, loss to follow-up and transfer out 
There was substantial heterogeneity between regions in overall mortality rate, disease 
characteristics and age. Crude mortality was highest in the Western Cape which includes the 
only exclusively tertiary care treatment sites and has the highest proportion of children <2 years 
initiating treatment. These sites rapidly transfer children to primary care once they are getting 
better (12.7% TFO from Western Cape tertiary care sites between six and twelve months on 
ART)35 which may result in over-estimating mortality. We excluded children LTFU/TFO within 
six months of starting ART to reduce bias by underascertainment of deaths if these patients had 
been included and censored. This does not completely remove bias as children classified as 
LTFU may have died before meeting the LTFU definition and mortality might be higher in 
children LTFU compared to children remaining in care.11 36,37 Our sensitivity analysis including 
children LTFU/TFO within six months of ART start showed that assumptions about their 
mortality impact on estimated overall mortality, and their exclusion may result in underestimated 
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predicted mortality at the program level. Indeed, excluded children were more likely to have 
characteristics associated with mortality compared to those included in the main analysis. 
Comparison to pre-ART prognostic model 
While predictors of mortality pre-ART and on ART have been examined in developing and 
wealthy countries, this is the first prognostic model for children on ART.6,7,9,13,18,38 A similar 
model for pre-ART mortality has been developed in children from high income settings.8 A 
weighted score incorporating weight percentile, WHO stage, symptoms, general health rating, 
total lymphocyte count, packed cell volume and albumin predicted mortality well with a C-
statistic of 0.852 (higher than the values of 0.753 and 0.745 for our models with and without 
CD4% respectively). The study also showed that CD4% can be replaced by simpler measures to 
predict pre-ART mortality and so could be applied to resource-limited settings where CD4% is 
not routinely available. However, as expected from high income settings, children had less 
advanced disease. Furthermore, the mothers of all children participated in a randomized trial and 
the model may not be applicable to routine care in resource-limited settings. 
Comparison with adult model 
Our pediatric model compares favorably with the adult model for resource-limited settings 
(higher R2 and C-statistic).11 This is probably due to the powerful prognostic value of age in 
children. Mortality declines rapidly with increasing age in all children, irrespective of HIV-
infection. In the context of ART eligibility in a perinatally HIV-infected child only after 
“waiting” for disease severity criteria to be met, the age at therapy start is a proxy for rate of 
disease progression since birth and thus a strong prognostic factor.3 The model predictions may 
therefore not be applicable to children <5 years who start ART without clinical/immunological 
progression as recommended in the WHO guidelines.39,40 The Children with HIV Early 
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Antiretroviral Therapy (CHER) trial demonstrated a better prognosis in infants starting ART 
before disease progression.41  
Utility of the models 
The likely mortality of a patient with a particular set of characteristics can be determined using 
the supplementary tables in this paper. This may be useful for guiding clinicians and patients 
regarding prognosis, and for risk stratification. In a similar way the HIV Pediatric Prognostic 
Markers Collaborative Study (HPPMCS) online calculator for pre-ART mortality has been used 
to guide decisions on when to start ART in Europe.6 Our models are useful for program 
planning, and their generalizability makes them useful for comparing outcomes across different 
programs after adjusting appropriately for different patient disease severity. 
Strengths and limitations 
To our knowledge this is the first pediatric prognostic model of mortality on ART and is based 
on a very large cohort across a range of settings. The large number of missing values for some 
variables (e.g. hemoglobin) is a limitation. In particular, this limited our ability to determine 
whether a model based on hemoglobin alone was as good as including CD4% and hemoglobin 
for prognostic purposes. Due to imputation of a large proportion of hemoglobin values for all 
regions except Zambia, there was misfit of predicted mortality at the level of the region for the 
model without CD4% (Figure 1[c]]). However, there was little difference in measures of fit when 
restricting to patients in whom hemoglobin was measured, and the fit of the models with and 
without CD4% were comparable in Zambia for which <20% of hemoglobin values were 
imputed. In addition, associations with mortality were similar if missing values were imputed or 
a complete case analysis was performed. This, together with the cross validation, underlines the 
robustness of our findings. The majority of children in this analysis started ART with advanced 
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
  15 
disease, hence we were unable to examine mortality for higher values of CD4% and WAZ. 
Nevertheless, the model predictions are applicable to most children starting ART as the majority 
of children in this region still commence ART with advanced disease.42,43 
Despite the fact that many sites from different settings are represented, the good fit between 
predicted and observed mortality for different prognostic groups (figure 1[a]) may be driven by 
the large MoH-CIDRZ region where concordance at a regional level was also good. 
Discrepancies between predicted and observed mortality for other regions may be due to 
differences in LTFU and mortality ascertainment, proportion of imputed data, differences in 
prognostic variables not measured or included in the models or differences in background 
mortality, access to health services and models of care. Other factors such as nutrition 
supplements, co-trimoxazole prophylaxis, co-infections including malaria, first-line regimen, 
adherence, HIV-1 RNA and exposure to vertical transmission prevention regimens may be 
associated with outcomes in children.15,44-47 However, these factors are often not easily available. 
There is a trade-off between models which would be more accurate but less applicable and useful 
in general health care settings in low-income countries. Poor availability of any of the variables 
in our models would limit their utility, hence developing models both with and without CD4 
percent. This may be increasingly important if programs phase out CD4 monitoring with 
increasing emphasis on universal ART for children irrespective of CD4 values and on routine 
HIV-RNA monitoring. In this respect, the poor availability of hemoglobin values is a concern, 
however likely reflects failure to record rather than measure these values. Many of the sites that 
had low proportions of hemoglobin recorded have reasonable access to laboratory testing or 
point of care hemoglobinometers and it is likely that hemoglobin values would be available for a 
clinician wanting to use them for prognostication. In addition all children came from largely 
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
  16 
urban regions and all sites had medical record systems available, limiting generalizability to less 
well-resourced cohorts and primary care facilities where pediatric ART increasingly occurs.  
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Region Western Cape Gauteng Kwazulu-Natal
Malawi & 
Zimbabwe
Zambia Total 
Number of children 1505 (14%) 2015 (19%) 791 (7%) 706 (6%) 5858 (54%) 10875
Sex  
    Female 720 (48%) 997 (49%) 396 (50%) 364 (52%) 2883 (49%) 5360 (49%)
    Male 785 (52%) 1018 (51%) 395 (50%) 342 (48%) 2975 (51%) 5515 (51%)
Age group
    < 1 year 441 (29%) 306 (15%) 74 (9%) 23 (3%) 583 (10%) 1427 (13%)
    1 year 290 (19%) 282 (14%) 128 (16%) 71 (10%) 1008 (17%) 1779 (16%)
    2-4 years 412 (27%) 629 (31%) 224 (28%) 219 (31%) 1809 (30%) 3293 (30%)
    5-10 years 362 (24%) 798 (40%) 365 (46%) 393 (56%) 2458 (40%) 4376 (40%)
WHO Stage
1
    I/II 241 (18%) 461 (41%) 98 (19%) 37 (6%) 1746 (31%) 2583 (28%)
    III/IV 1078 (82%) 669 (59%) 428 (81%) 538 (94%) 3964 (69%) 6677 (72%)
    Not reported 186 (12%) 885 (44%) 265 (34%) 131 (18%) 148 (3%) 1615 (15%)
Anemia
1
   Mild/none 903 (83%) 209 (87%) 464 (85%) 196 (87%) 3736 (78%) 5508 (80%)
   Moderate 114 (10%) 18 (8%) 54 (10%) 18 (8%) 590 (12%) 794 (12%)
   Severe 72 (7%) 13 (5%) 31 (6%) 11 (5%) 461 (10%) 588 (9%)
   Not reported 416 (28%) 1775 (88%) 242 (31%) 481 (68%) 1071 (18%) 3985 (37%)
Median (IQR) CD4% 13 (9 to 19)% 11 (7 to 15)% 13 (8 to 17)% 14 (9 to 20)% 14 (9 to 20)% 13 (8 to 19)%
    Not reported 460 (31%) 313 (16%) 230 (29%) 397 (56%) 2080 (36%) 3480 (32%)
Median (IQR) WAZ -1.9 (-3.5 to -0.8) -2.0 (-3.1 to -1.1) -1.4 (-2.5 to -0.5) -1.8 (-2.9 to -0.8) -2.2 (-3.3 to -1.1) -2.0 (-3.2 to -1.0)
    Not reported 537 (36%) 385 (19%) 168 (21%) 213 (30%) 319 (5%) 1622 (15%)
Median (IQR) log10HIV-RNA 
(copies/ml)
5.56 (4.97 to 6.09) 5.23 (4.69 to 5.79) 4.52 (3.81 to 5.26) 5.09 (4.62 to 5.45) 5.27 (4.69 to 5.84)
   Not reported 430 (29%) 516 (26%) 459 (58%) 578 (82%) 5856 (>99%) 7839 (72%)
Year of ART initiation
   2004 487 414 47 78 261 1287
   2005 572 884 123 188 812 2579
   2006 433 706 144 101 994 2378
   2007 13 11 158 80 1244 1506
   >2008 0 0 319 259 2547 3125
Follow-up (child years) 1377.9 1920.5 754.0 671.7 5480.2 10204.3
AT 1 YEAR
2
    % in follow-up        86.4 92.3 92.0 89.7 87.3 88.6
    % transferred 3.3 0.8 0.3 2.5 0 0.8
    % LTFU 0.7 1.1 1.3 2.3 3.7 2.5
    % deceased 9.6 5.8 6.4 5.5 9.0 8.1
1-year mortality rate
    K-M estimate (95% CI) 10.5 (8.9 to 12.4) 6.0 (5.0 to 7.2) 6.8 (5.1 to 8.9) 5.8 (4.2 to 7.9) 9.6 (8.8 to 10.5) 8.6 (8.0 to 9.2)
2
Note that LTFU and transferred outcomes refer to children LTFU or transferred between 6 and 12 months after antiretroviral therapy (ART) start as 
children LTFU/TFO within 6 months of ART start were excluded from the main analysis.
1
Note that percentages for particular categories of this variable are calculated with the denominator being the number of children in whom this variable 
was reported.
IQR: interquartile range; LTFU: loss to follw-up; K-M: Kaplan-Meier
Table 1: Pediatric antiretroviral therapy (ART) programs with number of patients, characteristics 
at ART initiation, follow-up duration, status by 1 year after ART initiation and Kaplan-Meier 
estimates of mortality by 1 year after ART initiation. 
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Variable
Available 
data
N(%) 
missing
Person 
years
N deaths
HR (95% CI) p-value HR (95% CI) p-value
Age (years) 877
  < 1 1427 1221 260 1 1
  1 1779 1588 261 0.74 (0.62 to 0.88) 0.001 0.72 (0.39 to 1.33)
1 0.291
  2-4 3293 3152 187 0.27 (0.23 to 0.33) <0.001 0.31 (0.17 to 0.57)
1 <0.001
  5-10 4376 4243 169 0.18 (0.15 to 0.22) <0.001 0.28 (0.17 to 0.46)
1 <0.001
Sex
  Male 5515 5178 438 1 1
  Female 5360 5026 439 1.04 (0.91 to 1.18) 0.598 1.06 (0.93 to 1.21) 0.372
Stage 1615 (15)
  Less advanced 2583 2503 111 1 1
  Advanced 6677 6179 650 2.21 (1.80 to 2.71) <0.001 1.93 (1.58 to 2.37) <0.001
CD4 percent 3480 (32)
   less than 5 854 766 114 1 1
   5 to 9 1588 1479 143 0.72 (0.57 to 0.91) 0.006 0.84 (0.51 to 1.38)
2 0.490
   10 to 14 2036 1936 141 0.59 (0.47 to 0.75) <0.001 0.57 (0.34 to 0.96)
2 0.035
   ≥ 15 2917 2733 238 0.64 (0.52 to 0.79) <0.001 0.59 (0.38 to 0.92)
2 0.021
Anemia 3985 (36)
   Severe 588 509 104 1 1
   Moderate 794 710 113 0.80 (0.62 to 1.03) 0.080 0.83 (0.64 to 1.08) 0.165
   Mild/none 5508 5206 401 0.43 (0.35 to 0.53) <0.001 0.61 (0.49 to 0.75) <0.001
Weight-for-age z-score 1622 (15)
   ≤ - 3 2715 2373 451 1 1
   -3 to -2 1975 1852 163 0.51 (0.43 to 0.61) <0.001 0.90 (0.62 to 1.29)
3 0.560
   -2 to -1 2258 2191 87 0.27 (0.21 to 0.33) <0.001 0.83 (0.57 to 1.21)
3 0.332
     ≥ -1 2305 2251 70 0.21 (0.17 to 0.27) <0.001 0.52 (0.35 to 0.80)
3 0.003
Crude mortality HR                                       
n=10875
Adjusted mortality HR               
n=10875
Analysis based on imputed data                                                                         
(25 multiple imputation datasets)
1 
HRs are shown for a child with CD4 percent <5%; 
2 
HRs are shown for a child < 1 year of age;
3
 HRs are shown for a child <1 year of age 
with CD4 percent <5%
HR: hazard ratio; CI: confidence interval
 Table 2 (a): Prognostic variables and mortality for children starting ART and not LTFU or TFO 
during the first 6 months of treatment in 11 treatment programs in Southern Africa. Note: results 
shown only for imputed data; results for complete cases were similar. 
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Table 2 (b): Hazard ratios for the associations between age, CD4% and weight-for-age z-score 
(WAZ) adjusted for these variables as well as WHO Clinical Stage and sex, taking into account 
the interactions between age and CD4% and age and WAZ for data with missing covariate 
values modeled using multiple imputation (N=10875)  
AGE WAZ CD4% <5 CD4% 5-9.9 CD4% 10-14.9 CD4% ≥ 15
 < 1 year < -3 1 0.87 (0.52 to 1.44) 0.60 (0.36 to 1.00) 0.62 (0.40 to 0.98)
-3 to -2 0.90 (0.62 to 1.29) 0.78 (0.41 to 1.45) 0.54 (0.29 to 0.98) 0.56 (0.32 to 0.97)
-2 to -1 0.83 (0.57 to 1.21) 0.72 (0.38 to 1.36) 0.50 (0.26 to 0.95) 0.52 (0.29 to 0.92)
≥ -1 0.52 (0.35 to 0.80) 0.45 (0.24 to 0.87) 0.31 (0.16 to 0.60) 0.33 (0.18 to 0.59)
1 year < -3 0.88 (0.47 to 1.65) 0.60 (0.35 to 1.02) 0.73 (0.43 to 1.22) 0.49 (0.30 to 0.80)
-3 to -2 0.66 (0.34 to 1.31) 0.45 (0.26 to 0.81) 0.55 (0.31 to 0.98) 0.37 (0.22 to 0.63)
-2 to -1 0.31 (0.15 to 0.67) 0.22 (0.11 to 0.43) 0.26 (0.12 to 0.51) 0.18 (0.09 to 0.33)
≥ -1 0.26 (0.11 to 0.57) 0.17 (0.09 to 0.35) 0.21 (0.11 to 0.41) 0.14 (0.07 to 0.27)
2-4 years < -3 0.50 (0.27 to 0.92) 0.43 (0.25 to 0.73) 0.26 (0.15 to 0.46) 0.32 (0.19 to 0.52)
-3 to -2 0.21 (0.11 to 0.42) 0.18 (0.10 to 0.33) 0.11 (0.06 to 0.15) 0.13 (0.07 to 0.24)
-2 to -1 0.09 (0.04 to 0.20) 0.08 (0.04 to 0.16) 0.05 (0.02 to 0.10) 0.06 (0.03 to 0.12)
≥ -1 0.10 (0.05 to 0.22) 0.09 (0.04 to 0.17) 0.05 (0.03 to 0.11) 0.06 (0.03 to 0.12)
5-9 years < -3 0.41 (0.25 to 0.68) 0.20 (0.11 to 0.35) 0.14 (0.08 to 0.27) 0.14 (0.08 to 0.26)
-3 to -2 0.22 (0.12 to 0.40) 0.11 (0.06 to 0.20) 0.07 (0.04 to 0.15) 0.08 (0.04 to 0.15)
-2 to -1 0.12 (0.06 to 0.23) 0.06 (0.03 to 0.11) 0.04 (0.02 to 0.08) 0.04 (0.02 to 0.08)
≥ -1 0.08 (0.04 to 0.18) 0.04 (0.02 to 0.09) 0.03 (0.01 to 0.06) 0.03 (0.01 to 0.06)
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Variable
Adjusted mortality HR 
(95% CI)
p-value
Adjusted mortality HR 
(95% CI)
p-value
Age
   <1 year 1 1
   1 year 0.78 (0.66 to 0.93) 0.006 0.78 (0.66 to 0.93) 0.005
   2 to 4 years 0.34 (0.28 to 0.41) <0.001 0.35 (0.29 to 0.43) <0.001
   5 to 10 years 0.22 (0.18 to 0.27) <0.001 0.25 (0.2 to 0.3) <0.001
WHO Clinical Stage
   I or II 1 1
   III or IV 1.39 (1.13 to 1.71) 0.002 1.39 (1.13 to 1.72) 0.002
CD4%
   <5% 1
   5-9.9% 0.69 (0.54 to 0.87) 0.002
   ≥10% 0.56 (0.45 to 0.68) <0.001
Weight-for-age z-score
   <-3 1 1
   -3 to -2 0.66 (0.55 to 0.79) <0.001 0.63 (0.53 to 0.76) <0.001
   ≥ -2 0.35 (0.29 to 0.42) <0.001 0.33 (0.27 to 0.4) <0.001
Anemia
   Severe 1 1
   Mild/moderate/none 0.71 (0.57 to 0.88) 0.002 0.7 (0.57 to 0.87) 0.001
HR: hazard ratio; CI: confidence interval
Model with CD4% Model without CD4%
not in model
not in model
not in model
Table 3: Adjusted mortality hazard ratios (HR) in the selected best models with CD4% and 
withoutCD4% 
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Figure 1 (a): Cumulative mortality predicted from prognostic models (dashed lines) compared 
with Kaplan-Meier observed mortality (solid lines) for five prognostic groups of children 
commencing antiretroviral therapy, ranging from worst to best prognosis. Prognostic groups 
were defined by ranking the children in order of mortality risk according to their risk factors. 
Mortality risk was estimated by the linear predictor of the prognostic model. The cut-points for 
each prognostic group were determined so that each group contained approximately 20% of 
deaths and were ordered from low to high risk. Number of patients in each group (%) is shown. 
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Figure 1 (b): Cumulative mortality predicted from prognostic models (dashed lines) compared 
with Kaplan-Meier observed mortality (solid lines) for each region for three prognostic groups of 
children commencing antiretroviral therapy, ranging from worst to best prognosis. Prognostic 
groups were defined as for figure 1 (a) but only three prognostic groups were used due to the 
smaller number of children for individual regions. Each group contains approximately one third 
of deaths.  
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Figure 1 (c): Cumulative mortality predicted from prognostic models (solid lines) compared with 
Kaplan-Meier observed mortality for each region (dashed lines) for patients with the most 
commonly occurring values of prognostic variables. Patients were age 5-10 years with WHO 
Stage III/IV disease, CD4≥10% and weight-for-age z-score -3 to -2. 
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 Age < 1 year
WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 23.1 17.5 to  30.1 17.4 13.6 to  22.0 17.4 13.2 to  22.7 12.9 10.2 to  16.3 14.0 10.8 to 18.0 10.4 8.4 to 12.8
<-3 6 31.3 24.1 to 40.0 23.8 18.9 to 29.9 23.9 18.4 to 30.7 18.0 14.3 to 22.4 19.4 15.1 to 24.7 14.5 11.8 to 17.7
<-3 12 38.5 30.1 to 48.4 29.7 23.8 to 36.8 29.8 23.1 to 37.8 22.6 18.2 to 28.0 24.4 19.2 to 30.7 18.4 15.0 to 22.3
-3 to  -2 3 15.3 11.2 to 20.6 11.3 8.6 to 14.9 11.3 8.3 to 15.3 8.4 6.4 to 10.9 9.1 6.8 to 12.0 6.7 5.2 to 8.5
-3 to  -2 6 21.1 15.6 to 28.1 15.8 12.0 to 20.5 15.8 11.7 to 21.1 11.7 9.0 to 15.1 12.7 9.6 to 16.6 9.4 7.4 to 11.8
-3 to  -2 12 26.4 19.8 to 34.7 19.9 15.3 to 25.7 20.0 15.0 to 26.4 14.9 11.6 to 19.2 16.1 12.3 to 21.0 12.0 9.5 to 15.0
>=-2 3 9.4 6.9 to 12.9 7.0 5.3 to 9.1 7.0 5.1 to 9.4 5.1 4.0 to 6.5 5.5 4.2 to 7.3 4.1 3.3 to 5.0
>=-2 6 13.2 9.7 to 17.9 9.8 7.5 to 12.7 9.8 7.3 to 13.2 7.2 5.6 to 9.2 7.8 6.0 to 10.2 5.7 4.7 to 7.1
>=-2 12 16.8 12.4 to 22.6 12.5 9.6 to 16.1 12.5 9.3 to 16.7 9.2 7.3 to 11.7 10.0 7.7 to 13.1 7.4 6.0 to 9.0
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 28.5 22.8 to 35.3 21.6 17.9 to 25.9 21.6 17.2 to 27.0 16.2 13.5 to 19.4 17.5 14.4 to 21.3 13.0 11.3 to 15.0
<-3 6 38.1 31.0 to 46.2 29.4 24.7 to 34.7 29.4 23.7 to 36.1 22.3 18.8 to 26.4 24.1 19.9 to 28.9 18.1 15.9 to 20.6
<-3 12 46.3 38.2 to 55.2 36.3 30.8 to 42.5 36.3 29.6 to 44 27.9 23.7 to 32.7 30.0 25.1 to 35.7 22.8 20.1 to 25.8
-3 to  -2 3 19.0 14.6 to 24.7 14.2 11.2 to 17.9 14.2 10.9 to 18.5 10.5 8.4 to 13.2 11.4 9.0 to 14.4 8.4 7.0 to 10.1
-3 to  -2 6 26.1 20.2 to 33.3 19.7 15.7 to 24.5 19.7 15.2 to 25.3 14.7 11.8 to 18.3 15.9 12.7 to 19.9 11.8 9.9 to 14.1
-3 to  -2 12 32.4 25.4 to 40.8 24.7 19.9 to 30.5 24.8 19.3 to 31.4 18.6 15.1 to 23 20.1 16.1 to 25.0 15.1 12.6 to 17.9
>=-2 3 11.9 8.9 to 15.9 8.8 6.9 to 11.2 8.8 6.6 to 11.7 6.5 5.1 to 8.1 7.0 5.5 to 9.0 5.1 4.3 to 6.2
>=-2 6 16.6 12.5 to 21.9 12.3 9.7 to 15.5 12.3 9.3 to 16.2 9.1 7.3 to 11.4 9.9 7.7 to 12.6 7.3 6.1 to 8.6
>=-2 12 20.9 15.8 to 27.3 15.7 12.4 to 19.6 15.7 11.9 to 20.5 11.6 9.4 to 14.4 12.6 9.9 to 16.0 9.3 7.9 to 11.0
CD4 percent <5% CD4 percent 5-9.9% CD4 percent ≥10%
Severe anaemia Severe anaemia Severe anaemiaModerate/mild/no anaemia Moderate/mild/no anaemia Moderate/mild/no anaemia
Appendix Table S1 (a): Estimates of cumulative mortality at 3, 6 and 12 months after ART start from the model with CD4%  
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 Age 1 year
WHO Stage I or II
Moderate/mild/no anaemia Moderate/mild/no anaemia Moderate/mild/no anaemia
WAZ Months Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 18.5 13.9 to 24.3 13.8 10.7 to 17.6 13.8 10.4 to 18.1 10.2 8.0 to 12.9 11.1 8.5 to 14.3 8.2 6.5 to 10.1
<-3 6 25.3 19.3 to 32.8 19.1 14.9 to 24.2 19.1 14.6 to 24.7 14.3 11.3 to 17.9 15.4 12.0 to 19.7 11.4 9.2 to 14.1
<-3 12 31.5 24.3 to 40.2 24.0 18.9 to 30.1 24.0 18.5 to 30.8 18.1 14.4 to 22.5 19.5 15.3 to 24.8 14.6 11.8 to 17.9
-3 to  -2 3 12.1 8.8 to 16.4 8.9 6.7 to 11.8 8.9 6.6 to 12.0 6.6 5.0 to 8.5 7.1 5.4 to 9.4 5.2 4.1 to 6.6
-3 to  -2 6 16.8 12.4 to 22.5 12.5 9.5 to 16.4 12.5 9.3 to 16.7 9.2 7.1 to 11.9 10.0 7.6 to 13.1 7.4 5.8 to 9.3
-3 to  -2 12 21.2 15.7 to 28.2 15.9 12.1 to 20.7 15.9 11.9 to 21.1 11.8 9.1 to 15.2 12.8 9.7 to 16.7 9.4 7.5 to 11.9
>=-2 3 7.4 5.4 to 10.2 5.4 4.1 to 7.1 5.4 4.0 to 7.4 4.0 3.1 to 5.1 4.3 3.3 to 5.7 3.2 2.5 to 3.9
>=-2 6 10.4 7.6 to 14.2 7.7 5.9 to 10.0 7.7 5.7 to 10.3 5.6 4.4 to 7.2 6.1 4.7 to 8.0 4.5 3.6 to 5.5
>=-2 12 13.3 9.8 to 18.0 9.8 7.6 to 12.8 9.9 7.3 to 13.2 7.3 5.7 to 9.2 7.9 6.0 to 10.3 5.8 4.7 to 7.1
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 22.9 18.2 to 28.7 17.2 14.2 to 20.8 17.2 13.7 to 21.5 12.8 10.7 to 15.4 13.9 11.4 to 16.9 10.3 8.9 to 11.9
<-3 6 31.1 25.0 to 38.2 23.7 19.7 to 28.3 23.7 19.1 to 29.2 17.8 15.0 to 21.1 19.2 15.9 to 23.2 14.4 12.5 to 16.5
<-3 12 38.3 31.2 to 46.4 29.5 24.8 to 35.0 29.6 24.0 to 36.1 22.5 19.0 to 26.4 24.2 20.1 to 29.0 18.2 16.0 to 20.7
-3 to  -2 3 15.1 11.5 to 19.7 11.2 8.8 to 14.2 11.2 8.6 to 14.6 8.3 6.6 to 10.4 9.0 7.1 to 11.3 6.6 5.5 to 8.0
-3 to  -2 6 20.9 16.1 to 26.9 15.6 12.4 to 19.6 15.7 12.1 to 20.1 11.6 9.4 to 14.4 12.6 10.0 to 15.8 9.3 7.8 to 11.1
-3 to  -2 12 26.2 20.4 to 33.3 19.8 15.8 to 24.6 19.8 15.4 to 25.2 14.8 12.0 to 18.2 16.0 12.8 to 19.9 11.9 10.0 to 14.1
>=-2 3 9.4 7.0 to 12.6 6.9 5.4 to 8.8 6.9 5.2 to 9.2 5.1 4.0 to 6.3 5.5 4.3 to 7.0 4.0 3.3 to 4.8
>=-2 6 13.1 9.8 to 17.4 9.7 7.6 to 12.3 9.7 7.4 to 12.8 7.1 5.7 to 8.9 7.8 6.1 to 9.9 5.7 4.8 to 6.8
>=-2 12 16.7 12.6 to 21.9 12.4 9.8 to 15.6 12.4 9.4 to 16.2 9.2 7.4 to 11.4 9.9 7.8 to 12.6 7.3 6.2 to 8.7
CD4 percent <5% CD4 percent 5-9.9% CD4 percent ≥10%
Severe anaemia Severe anaemia Severe anaemia
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 Age 2-4 years
WHO Stage I or II
Moderate/mild/no anaemia Moderate/mild/no anaemia Moderate/mild/no anaemia
WAZ Months Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 8.8 6.5 to 11.8 6.5 5.0 to 8.4 6.5 4.8 to 8.6 4.7 3.7 to 6.1 5.2 3.9 to 6.8 3.8 3.0 to 4.8
<-3 6 12.3 9.2 to 16.4 9.1 7.1 to 11.7 9.1 6.9 to 12.1 6.7 5.3 to 8.5 7.3 5.5 to 9.6 5.3 4.2 to 6.7
<-3 12 15.7 11.8 to 20.7 11.7 9.1 to 14.9 11.7 8.8 to 15.3 8.6 6.8 to 10.9 9.3 7.1 to 12.2 6.9 5.5 to 8.6
-3 to  -2 3 5.6 4.1 to 7.7 4.1 3.1 to 5.5 4.1 3.0 to 5.6 3.0 2.3 to 3.9 3.3 2.4 to 4.4 2.4 1.9 to 3.1
-3 to  -2 6 8.0 5.8 to 10.8 5.8 4.4 to 7.7 5.9 4.3 to 7.9 4.3 3.3 to 5.5 4.7 3.5 to 6.2 3.4 2.7 to 4.3
-3 to  -2 12 10.2 7.5 to 13.8 7.5 5.7 to 9.8 7.5 5.6 to 10.1 5.5 4.3 to 7.1 6.0 4.5 to 7.9 4.4 3.4 to 5.6
>=-2 3 3.4 2.5 to 4.7 2.5 1.9 to 3.2 2.5 1.8 to 3.4 1.8 1.4 to 2.3 2.0 1.5 to 2.6 1.4 1.2 to 1.8
>=-2 6 4.9 3.5 to 6.6 3.5 2.7 to 4.6 3.6 2.6 to 4.8 2.6 2.0 to 3.3 2.8 2.1 to 3.7 2.1 1.7 to 2.5
>=-2 12 6.2 4.6 to 8.5 4.6 3.5 to 5.9 4.6 3.4 to 6.1 3.3 2.7 to 4.2 3.6 2.8 to 4.8 2.7 2.2 to 3.3
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 11.1 8.6 to 14.2 8.2 6.6 to 10.1 8.2 6.4 to 10.5 6.0 4.9 to 7.3 6.5 5.2 to 8.2 4.8 4.0 to 5.7
<-3 6 15.5 12.1 to 19.7 11.5 9.4 to 14.0 11.5 9.0 to 14.6 8.5 7.0 to 10.3 9.2 7.4 to 11.5 6.8 5.7 to 8.0
<-3 12 19.6 15.4 to 24.7 14.6 12.0 to 17.8 14.6 11.6 to 18.5 10.9 9.0 to 13.1 11.8 9.4 to 14.6 8.7 7.4 to 10.2
-3 to  -2 3 7.1 5.4 to 9.5 5.2 4.1 to 6.7 5.2 4.0 to 6.9 3.8 3.0 to 4.8 4.2 3.2 to 5.4 3.0 2.5 to 3.7
-3 to  -2 6 10.1 7.6 to 13.2 7.4 5.8 to 9.4 7.4 5.7 to 9.7 5.4 4.3 to 6.8 5.9 4.6 to 7.5 4.3 3.6 to 5.3
-3 to  -2 12 12.8 9.8 to 16.7 9.5 7.5 to 11.9 9.5 7.3 to 12.4 7.0 5.6 to 8.7 7.6 5.9 to 9.6 5.6 4.6 to 6.7
>=-2 3 4.3 3.2 to 5.9 3.2 2.5 to 4.1 3.2 2.4 to 4.2 2.3 1.8 to 2.9 2.5 1.9 to 3.3 1.8 1.5 to 2.2
>=-2 6 6.2 4.6 to 8.2 4.5 3.5 to 5.7 4.5 3.4 to 6.0 3.3 2.6 to 4.1 3.6 2.8 to 4.6 2.6 2.2 to 3.1
>=-2 12 7.9 5.9 to 10.5 5.8 4.6 to 7.3 5.8 4.4 to 7.7 4.3 3.4 to 5.3 4.6 3.6 to 5.9 3.4 2.8 to 4.0
CD4 percent <5% CD4 percent 5-9.9% CD4 percent ≥10%
Severe anaemia Severe anaemia Severe anaemia
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 Age 5-10 years
WHO Stage I or II
Moderate/mild/no anaemia Moderate/mild/no anaemia Moderate/mild/no anaemia
WAZ Months Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 6.2 4.6 to 8.3 4.5 3.5 to 5.8 4.5 3.3 to 6.1 3.3 2.6 to 4.2 3.6 2.7 to 4.8 2.6 2.1 to 3.3
<-3 6 8.7 6.5 to 11.6 6.4 5.0 to 8.2 6.4 4.8 to 8.6 4.7 3.7 to 6.0 5.1 3.8 to 6.8 3.7 2.9 to 4.7
<-3 12 11.1 8.3 to 14.8 8.2 6.5 to 10.4 8.2 6.1 to 11.0 6.0 4.7 to 7.7 6.6 4.9 to 8.7 4.8 3.8 to 6.1
-3 to  -2 3 3.9 2.9 to 5.4 2.9 2.2 to 3.8 2.9 2.1 to 3.9 2.1 1.6 to 2.7 2.3 1.7 to 3.1 1.7 1.3 to 2.1
-3 to  -2 6 5.6 4.1 to 7.6 4.1 3.1 to 5.3 4.1 3.0 to 5.6 3.0 2.3 to 3.9 3.2 2.4 to 4.4 2.4 1.8 to 3.0
-3 to  -2 12 7.2 5.3 to 9.7 5.3 4.0 to 6.8 5.3 3.9 to 7.2 3.8 3.0 to 5.0 4.2 3.1 to 5.6 3.1 2.4 to 3.9
>=-2 3 2.4 1.7 to 3.3 1.7 1.3 to 2.2 1.7 1.3 to 2.4 1.3 1 .0 to 1.6 1.4 1.0 to 1.8 1.0 0.8 to 1.2
>=-2 6 3.4 2.5 to 4.6 2.5 1.9 to 3.2 2.5 1.8 to 3.4 1.8 1.4 to 2.3 2.0 1.5 to 2.6 1.4 1.1 to 1.8
>=-2 12 4.4 3.2 to 5.9 3.2 2.5 to 4.1 3.2 2.4 to 4.3 2.3 1.8 to 2.9 2.5 1.9 to 3.4 1.8 1.5 to 2.3
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 7.8 6.1 to 10.0 5.7 4.7 to 7.0 5.7 4.4 to 7.5 4.2 3.4 to 5.1 4.6 3.6 to 5.9 3.3 2.8 to 4.0
<-3 6 11.0 8.6 to 14.0 8.1 6.7 to 9.8 8.1 6.3 to 10.5 5.9 4.9 to 7.2 6.5 5.1 to 8.2 4.7 4.0 to 5.7
<-3 12 14.0 11.0 to 17.7 10.4 8.6 to 12.5 10.4 8.1 to 13.3 7.6 6.3 to 9.3 8.3 6.5 to 10.5 6.1 5.1 to 7.3
-3 to  -2 3 5.0 3.8 to 6.6 3.7 2.9 to 4.6 3.7 2.7 to 4.9 2.7 2.1 to 3.4 2.9 2.2 to 3.8 2.1 1.7 to 2.6
-3 to  -2 6 7.1 5.4 to 9.3 5.2 4.1 to 6.5 5.2 3.9 to 6.9 3.8 3.0 to 4.7 4.1 3.2 to 5.4 3.0 2.5 to 3.7
-3 to  -2 12 9.1 6.9 to 11.8 6.7 5.4 to 8.3 6.7 5.0 to 8.8 4.9 3.9 to 6.1 5.3 4.1 to 6.9 3.9 3.2 to 4.7
>=-2 3 3.0 2.2 to 4.1 2.2 1.8 to 2.8 2.2 1.6 to 3.0 1.6 1.3 to 2.0 1.8 1.3 to 2.3 1.3 1.0 to 1.6
>=-2 6 4.3 3.2 to 5.8 3.1 2.5 to 3.9 3.1 2.3 to 4.2 2.3 1.8 to 2.9 2.5 1.9 to 3.3 1.8 1.5 to 2.2
>=-2 12 5.5 4.1 to 7.4 4.1 3.2 to 5.0 4.1 3.0 to 5.4 3.0 2.4 to 3.7 3.2 2.5 to 4.2 2.3 1.9 to 2.8
CD4 percent <5% CD4 percent 5-9.9% CD4 percent ≥10%
Severe anaemia Severe anaemia Severe anaemia
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 Appendix Table S1 (b): Estimates of cumulative mortality at 3, 6 and 12 months after ART start 
from the model without CD4% 
 
Age < 1 year
WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI
<-3 3 15.8 12.3 to 20.2 11.6 9.4 to 14.2
<-3 6 21.8 17.2 to 27.5 16.1 13.2 to 19.5
<-3 12 27.3 21.7 to 34.0 20.3 16.8 to 24.5
-3 to -2 3 10.0 7.5 to 13.1 7.2 5.7 to 9.1
-3 to -2 6 13.9 10.6 to 18.1 10.1 8.1 to 12.7
-3 to -2 12 17.6 13.5 to 22.8 12.9 10.3 to 16.1
>=-2 3 6.0 4.5 to 7.9 4.3 3.5 to 5.3
>=-2 6 8.4 6.4 to 11.0 6.1 5.0 to 7.5
>=-2 12 10.8 8.3 to 14.0 7.8 6.4 to 9.5
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI
<-3 3 19.7 16.3 to 23.8 14.5 12.7 to 16.5
<-3 6 26.9 22.5 to 32.0 20.1 17.8 to 22.6
<-3 12 33.4 28.2 to 39.3 25.2 22.4 to 28.2
-3 to -2 3 12.5 9.9 to 15.7 9.1 7.6 to 10.9
-3 to -2 6 17.4 13.9 to 21.6 12.8 10.7 to 15.1
-3 to -2 12 21.9 17.7 to 27.1 16.2 13.7 to 19.1
>=-2 3 7.6 5.9 to 9.7 5.5 4.6 to 6.5
>=-2 6 10.6 8.3 to 13.5 7.7 6.5 to 9.1
>=-2 12 13.5 10.7 to 17.1 9.9 8.3 to 11.7
Age 1 year
WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI
<-3 3 12.5 9.7 to 16.0 9.1 7.4 to 11.2
<-3 6 17.4 13.6 to 22.0 12.7 10.4 to 15.5
<-3 12 21.9 17.3 to 27.5 16.2 13.3 to 19.6
-3 to -2 3 7.8 5.9 to 10.3 5.6 4.4 to 7.1
-3 to -2 6 11.0 8.4 to 14.3 8.0 6.3 to 10.0
-3 to -2 12 14.0 10.7 to 18.1 10.2 8.1 to 12.8
>=-2 3 4.7 3.5 to 6.1 3.4 2.7 to 4.1
>=-2 6 6.6 5.0 to 8.6 4.8 3.9 to 5.8
>=-2 12 8.5 6.5 to 11.0 6.1 5.0 to 7.5
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI
<-3 3 15.7 12.9 to 19.0 11.5 10.0 to 13.1
<-3 6 21.6 18.0 to 25.8 16.0 14.1 to 18.1
<-3 12 27.1 22.7 to 32.1 20.2 17.9 to 22.7
-3 to -2 3 9.9 7.8 to 12.4 7.1 6.0 to 8.6
-3 to -2 6 13.8 11.0 to 17.2 10.0 8.4 to 11.9
-3 to -2 12 17.5 14.1 to 21.6 12.8 10.8 to 15.2
>=-2 3 5.9 4.6 to 7.6 4.3 3.6 to 5.1
>=-2 6 8.3 6.5 to 10.6 6.0 5.1 to 7.2
>=-2 12 10.7 8.4 to 13.5 7.7 6.5 to 9.1
Severe anaemia
Severe anaemia
Moderate/mild/no anaemia
Moderate/mild/no anaemia
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Age 2-4 years
WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI
<-3 3 6.1 4.6 to 7.9 4.4 3.5 to 5.5
<-3 6 8.6 6.6 to 11.1 6.2 5.0 to 7.7
<-3 12 11.0 8.5 to 14.1 8.0 6.4 to 9.8
-3 to -2 3 3.7 2.8 to 5.0 2.7 2.1 to 3.4
-3 to -2 6 5.3 4.0 to 7.0 3.8 3.0 to 4.8
-3 to -2 12 6.8 5.2 to 9.0 4.9 3.9 to 6.2
>=-2 3 2.2 1.7 to 2.9 1.6 1.3 to 2.0
>=-2 6 3.2 2.4 to 4.1 2.3 1.8 to 2.8
>=-2 12 4.1 3.1 to 5.3 2.9 2.4 to 3.6
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI
<-3 3 7.7 6.2 to 9.6 5.6 4.7 to 6.5
<-3 6 10.8 8.7 to 13.3 7.8 6.7 to 9.1
<-3 12 13.8 11.2 to 16.9 10.0 8.7 to 11.6
-3 to -2 3 4.8 3.7 to 6.1 3.4 2.8 to 4.1
-3 to -2 6 6.7 5.3 to 8.5 4.8 4.0 to 5.8
-3 to -2 12 8.6 6.8 to 10.9 6.2 5.2 to 7.5
>=-2 3 2.8 2.2 to 3.6 2.0 1.7 to 2.4
>=-2 6 4.0 3.1 to 5.2 2.9 2.4 to 3.4
>=-2 12 5.2 4.0 to 6.6 3.7 3.1 to 4.4
Age < 5-10 years
WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI
<-3 3 4.6 3.5 to 6.0 3.3 2.6 to 4.1
<-3 6 6.5 4.9 to 8.5 4.7 3.8 to 5.8
<-3 12 8.3 6.3 to 10.8 6.0 4.8 to 7.4
-3 to -2 3 2.8 2.1 to 3.8 2.0 1.6 to 2.6
-3 to -2 6 4.0 3.0 to 5.3 2.9 2.3 to 3.6
-3 to -2 12 5.1 3.9 to 6.8 3.7 2.9 to 4.6
>=-2 3 1.7 1.2 to 2.2 1.2 1.0 to 1.5
>=-2 6 2.4 1.8 to 3.1 1.7 1.4 to 2.1
>=-2 12 3.1 2.3 to 4.0 2.2 1.8 to 2.7
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI
<-3 3 5.8 4.6 to 7.3 4.2 3.6 to 4.9
<-3 6 8.2 6.5 to 10.2 5.9 5.1 to 6.9
<-3 12 10.5 8.4 to 13.0 7.6 6.5 to 8.8
-3 to -2 3 3.6 2.8 to 4.6 2.6 2.1 to 3.1
-3 to -2 6 5.1 3.9 to 6.5 3.6 3.0 to 4.4
-3 to -2 12 6.5 5.1 to 8.3 4.7 3.9 to 5.6
>=-2 3 2.1 1.6 to 2.8 1.5 1.3 to 1.8
>=-2 6 3.0 2.3 to 3.9 2.2 1.8 to 2.6
>=-2 12 3.9 3.0 to 5.0 2.8 2.3 to 3.3
Severe anaemia
Severe anaemia
Moderate/mild/no anaemia
Moderate/mild/no anaemia
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 No (N=10875) Yes  (N=1780) p-va lue
AGE
    Median age in months  (IQR) 47 (21 to 80) 27 (14 to 64) <0.001
     <24 months  of age (%) 29% 46% <0.001
STAGE
    WHO Stage II I/IV disease (%) 72% 78% <0.001
CD4 PERCENT
    Median CD4% (IQR) 13.0 (8.3 to 18.5) 14.3 (9.4 to 21.2) <0.001
ANEMIA
    Severe anemia  (%) 9% 13% <0.001
WAZ
    Median WAZ (IQR) -2.03 (-3.23 to -1.01) -2.64 (-3.99 to -1.40) <0.001
    WAZ <-3 (%) 29% 43% <0.001
LTFU: los s  to fol low-up; TFO: transfer out; WAZ: weight-for-age z-s core
Patients  LTFU or TFO in the fi rs t 6 months  of treatment
Table S2: Characteristics of children included in the main analysis compared to those excluded 
due to being lost to follow-up (LTFU) or transferred out (TFO) within the first 6 months of 
treatment. P-values derived from Wilcoxon rank sum tests and chi2 tests for differences in 
medians and proportions between the 2 groups for continuous variables and categorical variables 
respectively. 
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and transfer out (TFO), and censoring dates for patients LTFU/TFO.
 
 
Legend 
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